Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 1.00 |
| ▸ | F7 | P08709 | 18/20 | 1.00 |
| ▸ | F3 | P13726 | 18/20 | 1.00 |
| ▸ | F2 | P00734 | 17/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.82 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.82 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.82 |
| ▸ | PLG | P00747 | 9/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840828 | 0.93 | F7 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL7656938 | 0.91 | F3 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL3813137 | 0.89 | F7 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL7657149 | 0.89 | F7 (0.82) | F10F7F3F2PRSS1 | |
| SCHEMBL3812834 | 0.89 | F10 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL3807432 | 0.89 | F7 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL3812577 | 0.88 | F7 (1.00) | F10F7F3F2PRSS1 | |
| SCHEMBL7664577 | 0.88 | F7 (0.82) | F10F7F3F2PRSS1 | |
| SCHEMBL7657501 | 0.87 | F3 (0.93) | F10F7F3F2PRSS1 | |
| SCHEMBL6433628 | 0.87 | F7 (0.77) | F10F7F3F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383731-B1 | BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS | BIOCRYST PHARM INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-6936719-B2 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6699994-B1 | ANTICOAGULANTS; INHIBITORS OF THROMBIN, BLOOD COAGULATION FACTORS VIIA, XA, FVIIA, TISSUE FACTOR, AND TRYPSIN | BIOCRYST PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | TFPI, SPINT2, TFPI2 | F10 30/4885F7 16/4885F3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.